medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-7-34-38medsovet-2919Research ArticleКонтрацепцияContraceptionВПЧ и ассоциированные с ним заболевания шейки матки у женщин, применяющих гормональные методы контрацепции: лечебно-диагностическая тактика при аномальных результатах цитологииHPV and HPV-associated cervical diseases in women, who use hormonal methods of contraception: diagnostic and treatment management of abnormal cytology test resultНазароваН. М.NazarovaN. M.

Назарова Нисо Мирзоевна – д.м.н., ведущий научный сотрудник.

117997, Россия, г. Москва, ул. Академика Опарина, д. 4.

Nazarova Niso Mirzoevna, Dr. of Sci. (Med.), Leading Researcher.

117997, Russia, Moscow, 4 Oparina str.

grab2@yandex.ruГусаковК. И.GusakovK. I.

Гусаков Кирилл Ильич – аспирант.

117997, Россия, г. Москва, ул. Академика Опарина, д. 4.

Gusakov Kirill Ilyich, a postgraduate student.

117997, Russia, Moscow, 4 Oparina str.

cgr.mastress@gmail.comCычеваE. Г.SychevaE. G.

Cычева Елена Геннадьевна – врач.

117997, Россия, г. Москва, ул. Академика Опарина, д. 4.

Sycheva Elena Gennadievna, a physician.

117997, Russia, Moscow, 4 Oparina str.

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской Федерации.РоссияFederal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation.Russian Federation201902042019073438Copyright © Назарова Н.М., Гусаков К.И., Cычева E.Г., 20192019Назарова Н.М., Гусаков К.И., Cычева E.Г.Nazarova N.M., Gusakov K.I., Sycheva E.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2919

Если у пользователей гормональных методов контрацепции, в том числе контрацептивного влагалищного кольца, диагностированы аномальные результаты цитологии, следует придерживаться диагностических мероприятий, направленных на выявление и лечение ВПЧ-ассоциированных заболеваний шейки матки. Влагалищное кольцо НоваРинг является эффективным, надежным и безопасным средством гормональной контрацепции, в том числе для женщин, ранее перенесших хирургическое лечение по поводу HSIL.

If abnormal cytology test results are identified in the users of hormonal methods of contraception, including a vaginal ring, they should adhere to diagnostic algorithms aimed at identifying and treating HPV-associated cervical diseases. NovaRing vaginal ring is an effective, reliable and safe method of hormonal contraception, including for women who have previously undergone surgical treatment of HSIL.

влагалищное кольцоНоваРингASCUSLSILцитологияВПЧ-тестvaginal ringNovaRingASCUSLSILcytologyHPV testReferencesTang Y., Zheng L., Yang S. et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in nonvaccinated women. Virology Journal. 2017;14:84.Tang Y., Zheng L., Yang S. et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in nonvaccinated women. Virology Journal. 2017;14:84.WHO/ICO Information Centre on HPV and Cancer. Russian Federation: Human Papillomavirus and Related Cancers, Fact Sheet 2016 (2016.12.15) [http://www.hpvcentre.net].WHO/ICO Information Centre on HPV and Cancer. Russian Federation: Human Papillomavirus and Related Cancers, Fact Sheet 2016 (2016.12.15) [http://www.hpvcentre.net].Wheeler C.M., Hunt W.C., Joste N.E. et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475–87Wheeler C.M., Hunt W.C., Joste N.E. et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101:475–87De Sanjose S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 2010;11:1048–56.De Sanjose S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol. 2010;11:1048–56.Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol.2014;234(4):431-5.Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol.2014;234(4):431-5.Halec G., Alemany L., Lloveras B. et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441-51.Halec G., Alemany L., Lloveras B. et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441-51.http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics.http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics.http://www.cancer.org/cancer/analcancer/detailedguide/anal-cancer-what-is-keystatistics.http://www.cancer.org/cancer/analcancer/detailedguide/anal-cancer-what-is-keystatistics.Cancer Statistics. Surveillance Epidemiology and End Results, National Cancer Institute. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Retrieved October 22, 2013.Cancer Statistics. Surveillance Epidemiology and End Results, National Cancer Institute. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Retrieved October 22, 2013.Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42.Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42.Katki H.A., Schiffman M., Castle P.E. et al. Fiveyear risk of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013;17:36–42.Katki H.A., Schiffman M., Castle P.E. et al. Fiveyear risk of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013;17:36–42.Gagea J.C., Huntb W. C., Schiffmana M. et al. Risk Stratification using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a Statewide Surveillance Program. Cancer Epidemiol Biomarkers Prev. 2016;25(1):36–42.Gagea J.C., Huntb W. C., Schiffmana M. et al. Risk Stratification using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a Statewide Surveillance Program. Cancer Epidemiol Biomarkers Prev. 2016;25(1):36–42.Arbyn M., Xu L., Verdoodt F. et al. Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;166(2):118-127.Arbyn M., Xu L., Verdoodt F. et al. Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;166(2):118-127.Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCPASCP Cervical Cancer Guideline Committee. CA Cancer J Clin. 2012;62:147–72.Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCPASCP Cervical Cancer Guideline Committee. CA Cancer J Clin. 2012;62:147–72.

The authors declare that there are no conflicts of interest present.